key: cord-0753828-ghjoh9m1
authors: Gaitzsch, Erik; Passerini, Verena; Khatamzas, Elham; Strobl, Carolin D.; Muenchhoff, Maximilian; Scherer, Clemens; Osterman, Andreas; Heide, Michael; Reischer, Anna; Subklewe, Marion; Leutbecher, Alexandra; Tast, Benjamin; Ruhle, Adrian; Weiglein, Tobias; Stecher, Stephanie-Susanne; Stemmler, Hans J.; Dreyling, Martin; Girl, Philipp; Georgi, Enrico; Wölfel, Roman; Mateyka, Laura; D’Ippolito, Elvira; Schober, Kilian; Busch, Dirk H.; Kager, Juliane; Spinner, Christoph D.; Treiber, Matthias; Rasch, Sebastian; Lahmer, Tobias; Iakoubov, Roman; Schneider, Jochen; Protzer, Ulrike; Winter, Christof; Ruland, Jürgen; Quante, Michael; Keppler, Oliver T.; von Bergwelt-Baildon, Michael; Hellmuth, Johannes; Weigert, Oliver
title: COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
date: 2021-06-28
journal: Hemasphere
DOI: 10.1097/hs9.0000000000000603
sha: fdb96c0075fecba45377174870e44b1d1672d370
doc_id: 753828
cord_uid: ghjoh9m1

The clinical and immunological impact of B-cell depletion in the context of coronavirus disease 2019 (COVID-19) is unclear. We conducted a prospectively planned analysis of COVID-19 in patients who received B-cell depleting anti-CD20 antibodies and chemotherapy for B-cell lymphomas. The control cohort consisted of age- and sex-matched patients without lymphoma who were hospitalized because of COVID-19. We performed detailed clinical analyses, in-depth cellular and molecular immune profiling, and comprehensive virological studies in 12 patients with available biospecimens. B-cell depleted lymphoma patients had more severe and protracted clinical course (median hospitalization 88 versus 17 d). All patients actively receiving immunochemotherapy (n = 5) required ICU support including long-term mechanical ventilation. Neutrophil recovery following granulocyte colony stimulating factor stimulation coincided with hyperinflammation and clinical deterioration in 4 of the 5 patients. Immune cell profiling and gene expression analysis of peripheral blood mononuclear cells revealed early activation of monocytes/macrophages, neutrophils, and the complement system in B-cell depleted lymphoma patients, with subsequent exacerbation of the inflammatory response and dysfunctional interferon signaling at the time of clinical deterioration of COVID-19. Longitudinal immune cell profiling and functional in vitro assays showed SARS-CoV-2-specific CD8(+) and CD4(+) T-effector cell responses. Finally, we observed long-term detection of SARS-CoV-2 in respiratory specimens (median 84 versus 12 d) and an inability to mount lasting SARS-CoV-2 antibody responses in B-cell depleted lymphoma patients. In summary, we identified clinically relevant particularities of COVID-19 in lymphoma patients receiving B-cell depleting immunochemotherapies.

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has led to a rapidly unfolding pandemic with extensive morbidity and mortality. [1] [2] [3] The clinical presentation of COVID-19 is highly variable, ranging from asymptomatic infection to respiratory failure with fatal outcome. [3] [4] [5] Several risk factors for severe clinical course have been described, including malignancies and immunocompromised state due to anticancer therapies. 2, [6] [7] [8] [9] Therefore, clinicians now have to balance the risks and benefit of providing state-of-the-art anticancer therapies and the possibility of more severe clinical course of SARS-CoV-2 infections. 10, 11 However, currently available guidelines are primarily based on expert opinion as data on specific malignancies and treatments is still limited. 12, 13 Standard treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL) frequently includes monoclonal anti-CD20 antibodies (eg, rituximab and obinutuzumab), which deplete B-cells for at least 6-9 months. 14,15 B-cell depletion could compromise adaptive antiviral immune responses, delay viral clearance, and prolong viral shedding [16] [17] [18] and lead to more severe disease course, higher risk of re-infection, and prolonged infectivity. [19] [20] [21] [22] [23] Here, we report a prospectively planned analysis of COVID-19 in patients from two university hospital registries who received B-cell depleting immunochemotherapies for B-NHL during the first wave of the COVID-19 pandemic in Europe. We provide a detailed analysis of the clinical course with a long-term follow-up along with in-depth profiling of the humoral, cellular and molecular immune responses in comparison to an age-and sexmatched cohort of COVID-19 patients without B-NHL.

Patients are part of the prospective COVID-19 registries of the University Hospital of the Ludwig-Maximilians-University (CORKUM, WHO Trial ID DRKS00021225) or the University Hospital of Technical University of Munich (COMRI). Patients were eligible for this study if they had SARS-CoV-2 infection confirmed by specific real-time polymerase chain reaction (RT-PCR) in a respiratory specimen. The study cohort consisted of patients who received B-cell depleting anti-CD20 antibody-containing immunochemotherapies (ICT) for B-NHL. The control cohort consisted of age-and sex-matched patients without B-NHL who were hospitalized because of symptomatic COVID-19 (See Supplemental Digital Figure 1 , http://links.lww.com/HS/A169, CONSORT diagram). We only included patients with available peripheral blood samples (collected centrally up to twice weekly as an optional part of the registries) to determine humoral, cellular and molecular immune profiles (See Supplemental Digital Figure 2 , http://links.lww.com/HS/A169). Clinical and routine laboratory data were prospectively collected within the COVID-19 registries and verified and complemented by individual chart review. Clinical deterioration was defined as the need of ICU support. Respiratory deterioration was defined as the need of mechanical ventilation.

Patient data were pseudonymized for analysis, and the study was approved by the local ethics committees (No: #20-245 and #221/20 S). Written informed consent was obtained from each patient or authorized by proxy before any study-related procedure.

RT-PCR from respiratory specimen and blood serum used targets in the N and E genes as previously described. 24 IgG against SARS-CoV-2 was detected in serum samples using Anti-SARS-CoV-2-ELISA targeting the spike domain S1, according to manufacturers' protocols (Euroimmune and Roche). 25 Additional technical details are provided in Supplemental Methods section, http://links.lww.com/HS/A169.

Culture for SARS-CoV-2 was performed as previously described. 26 In brief, Vero E6 cells were inoculated with patient respiratory samples (nasopharygeal swap or tracheal aspirate as indicated) and observed daily for a cytopathic effect up to day 7. If negative, an additional passage was performed and observed for another 7 days. On observation of a cytopathogenic effect, the supernatant was harvested and further analyzed for the presence of SARS-CoV-2 RNA by specific real-time PCR detecting the N gene.

Immune profiling of peripheral blood mononuclear cells (PBMCs) was done by 32-parameter flow cytometry according to previously published guidelines. 27 Flow cytometry measurements were performed on a CytoFLEX LX flow cytometer (Beckman Coulter) and data were analyzed using FlowJo, v10 (Tree Star Inc., Ashland, OR, USA). The commercial fluorochrome conjugated antibodies are listed in the Supplemental Methods, http://links.lww.com/HS/A169. 

Digital multiplexed gene expression profiling of PBMCs was performed as previously described. 28, 29 Briefly, RNA from PBMCs was isolated using the Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA concentration was measured by NanoDrop 1000 (ThermoFisher, Waltham, MA, USA) and 100 ng were assayed with the PanCancer Human IO 360 Panel according to the manufacturer's protocol (NanoString, Seattle, WA, USA). Normalization was performed by subtracting the mean + 2 SDs of negative control as a cutoff and adjustment for geometric mean of defined positive controls and defined housekeeping genes. Housekeeping gene normalization threshold was set at 0.1-to 10-fold.

All data and protocols are available to other investigators. For original data, please contact oliver.weigert@med.unimuenchen.de.

We enrolled a total of 12 patients who were hospitalized consecutively between March 26 and May 6, 2020 because of symptomatic COVID-19 confirmed by SARS-CoV-2-specific RT-PCR. Table 1 summarizes the patient and disease characteristics. The study cohort consisted of 6 patients (median age 69 yrs, range 43-72) who had received either rituximab-(R, n = 4) or obinutuzumab-(O, n = 2) based immunochemotherapy (ICT) as frontline treatment for follicular lymphoma (n = 3), diffuse large B-cell lymphoma (n = 2), or marginal-zone lymphoma (n = 1). Five patients (no. 1-5) were on active frontline treatment. Patients no. 1-5 had received R/O-CHOP, while patient no. 6 had completed R-Bendamustine ICT 5 months before her SARS-CoV-2 infection. The control cohort consisted of 6 ageand sex-matched COVID-19 patients with no history of B-NHL or B-cell depleting therapies (Table 1) .

We compared the known clinical risk factors for severe COVID-19 manifestation between B-cell depleted lymphoma patients and controls (Table 1) : 1 and 4 patients had arterial hypertension, 2 each had diabetes, 0 and 1 had chronic pulmonary disease, and 1 each was obese, respectively.

Patients undergoing B-cell depleting ICT had more severe and protracted clinical course Figure 1A summarizes the clinical course of all patients. The median hospitalization time was 88 days (range 72-155) for B-cell depleted lymphoma patients as compared to 17 days (range 6-23) for controls (Fig. 1B) . All lymphoma patients received COVID-19-directed therapies, including remdesivir (n = 2), high-dose steroids (n = 2), hydroxychloroquine (n = 1), immunoglobulins (n = 1), and COVID-19-convalescent plasma (n = 5). In addition, all lymphoma patients received antimicrobial therapies (Table 1 ). In the control cohort, only 2 patients received COVID-19-directed therapies (high-dose steroids, n = 1, and tocilizumab, n = 1).

All but 1 lymphoma patient (83%) required mechanical ventilation as compared to 2 control patients (33%). Respiratory failure developed in all lymphoma patients on active ICT (no. 1-5) within a median of 14 days (range 11-26 d) after the diagnosis of COVID-19, while patient no. 6 (who had completed ICT before her SARS-CoV-2 infection) had a remarkably mild clinical course. The median time on mechanical ventilation was 62 versus 10 days, the median ICU stay 68 versus 14 days. ICU management of B-cell depleted lymphoma patients was highly complex including extracorporeal membrane oxygenation (n = 1), continuous veno-venous hemodialysis (n = 3), and extracorporeal cytokine adsorption (CytoSorb, n = 1). After a median follow-up of 169 days (range 81-217), 5 patients were alive and Neutrophil recovery frequently coincided with hyperinflammation and clinical deterioration Overall, lymphoma patients had rising inflammatory markers in routine laboratory testing at the time of clinical deterioration, including C-reactive protein (CRP) and IL-6 serum levels ( Fig. 2A, B) . Respiratory deterioration coincided with leukocyte and neutrophil recovery (Fig. 2C, D) and a trend toward lower lymphocyte counts (Fig. 2E) , resulting in a massively increased neutrophil-lymphocyte-ratio (NLR, Fig. 2F ). Of note, 4 of 5 patients on active ICT had received granulocyte colony stimulating factor (G-CSF) injections to accelerate neutrophil recovery, there of 3 within 1 week before ICU admission. G-CSF was given as part of the R-CHOP14 protocol 30 in 2 patients (no. 2 and 4) or to treat chemotherapy-induced 

We next investigated the adaptive immune response in B-cell depleted SARS-CoV-2-infected patients (Fig. 3A) . Flow cytometry of PBMCs confirmed complete B-cell depletion in all lymphoma patients (Fig. 3B) . At the time of clinical deterioration, absolute lymphocyte counts dropped further in these patients (Fig. 3C) , but the fraction of CD8 + T-cells increased (Fig. 3D) . Furthermore, we noticed a shift from naïve phenotype to an effector memory (EM) subtype (Fig. 3E) . A similar predominance of EM as well as T-effector memory cells re-expressing CD45RA (TEMRA) was also seen in CD8 + T-cells from the B-cell depleted lymphoma patient with uncomplicated COVID-19 (Patient no. 6) and in CD8 + T-cells from control patients, all collected at later time points of the disease (Fig. 3E ). In CD4 + T-cells, the central memory (CM) phenotype fraction was generally larger compared to CD8 + T-cells, but we still observed a similar shift from naive T-cells to EM phenotype in B-cell depleted lymphoma patients (Fig. 3F, G) .

To investigate whether the expanding EM populations comprise bona fide virus-specific T-cells, we probed CD8 + and CD4 + T-cells from serially collected peripheral blood samples of B-cell depleted patients for their specificity towards SARS-CoV-2 spike protein.

Virus-specific T-cells were not detectable at early time points but became detectable during the course of the disease in all 3 evaluable cases. Time to first measurable SARS-CoV-2 reactive T-cells was highly variable, ranging from 35 to 77 days for CD8 + T-cells (Fig. 3H, I) and from 17 to 40 days for CD4 + T-cells (Fig. 3J, K) , respectively.

As activation of the monocyte-macrophage axis has been described before in severe COVID-19, 31 we determined the shift of monocyte phenotypes during the course of the disease (Fig. 3L, M) , distinguishing classical (CD14 + CD16 − ), intermediate (CD14 + CD16 + ), and nonclassical (CD14 dim CD16 + ) monocytes (Fig. 3N) . 32 While classical monocytes are critical for the initial inflammatory response, intermediate monocytes express higher levels of proinflammatory cytokines (including IL-1, IL-6, and IL-10), 33 and nonclassical monocytes exhibit distinct functional properties, including promotion of neutrophil adhesion to inflamed endothelium. 34 Interestingly, we observed (Fig. 3M, N) , which was more pronounced compared to controls.

To comprehensively characterize immune responses in B-cell depleted lymphoma patients versus controls on a transcriptional level, we performed immune gene expression profiling from PBMCs collected at early time points of COVID-19 (ie, before clinical deterioration) (Fig. 4A) . Unsupervised clustering clearly separated lymphoma patients from controls (see Supplemental Figure 3A , http://links.lww.com/HS/A169). We inferred abundances of individual PBMC populations by marker gene expression. As expected, B-cell depleted lymphoma patients had lower B-cell scores as compared to controls (see Supplemental Figure  4B , http://links.lww.com/HS/A169), showing significant and large fold lower expression of B-cell genes, including MS4A1 (CD20), CD19, CD79A, and FCRL2 (Fig. 4B) . Gene set analysis showed downregulation of the "lymphoid compartment" (Fig. 4C) , including lower expression of IL7R, CCR4, and CXCR4 (Fig. 4D ).

In contrast, macrophage and neutrophil scores were higher in B-cell depleted patients as compared to controls (see Supplemental Figure 4C , D, http://links.lww.com/HS/A169). Gene set analysis revealed that top differentially expressed genes were enriched within the biological pathways "cytokine and chemokine signaling," "interferon signaling," "myeloid compartment," and "cytotoxicity," including upregulation of IL10, IL18, CSF1R, and CSF3R (Fig. 4C, D) . Furthermore, differential gene expression showed large fold higher expression of C1QA and C1QB (Fig. 4B) , the first components of the classical serum complement cascade.

Longitudinal analysis of immune gene expression in PBMCs from B-cell depleted patients (Fig. 4E) showed a further increase in macrophage scores (Fig. 4F) as well as CD8 + T-cell scores (Fig.  4G) at the time of clinical deterioration. Gene set enrichment analysis (GSEA) over time showed significant enrichment of the GSEA MSigDB hallmark signature "inflammatory response," with further upregulation of IL10, IL1A, and CSF1 (Fig. 4H-K) . In summary, our immune gene expression indicates early hyperactivation of neutrophils and monocytes/macrophages, as well as the complement system in B-cell depleted patients with COVID-19, with subsequent exacerbation of the inflammatory response and dysfunctional interferon signaling at the time of clinical deterioration.

Long-term detection of replication-competent SARS-CoV-2 in B-cell depleted lymphoma patients Finally, we compared SARS-CoV-2 clearance kinetics in patients with and without B-cell depletion. B-cell depleted lymphoma patients had a markedly longer detectability of SARS-CoV-2 RNA in respiratory specimens compared to controls as assessed by RT-PCR (median 84 versus 12 d) (Fig. 5A-C) . To determine whether patients shed replication-competent virus, we tested respiratory specimens from 3 lymphoma patients for the presence of virus in cell culture. Remarkably, SARS-CoV-2 could be cultured from specimen of all tested patients, one patient (no. 4) harboring infectious virus for >20 weeks (Fig. 5B) . Two patients showed recurring viremia, 1 patient over a time period of >4 weeks. SARS-CoV-2-specific IgG antibodies (Fig. 5B ) could only be detected transiently at low levels in 3 B-cell depleted patients shortly after the administration of convalescent plasma. Similar results were obtained with a different antibody assay (see Supplemental Digital Figure 9 , http://links.lww.com/HS/ A169).

Through detailed analysis of the clinical course and comprehensive laboratory, immunological and virological studies, we identify several clinically relevant particularities of COVID-19 in patients with lymphoma who have received B-cell depleting immunochemotherapies.

First, patients on active immunochemotherapy have long and severe clinical courses. This is in line with earlier reports of severe COVID-19 in B-cell depleted patients. 35, 36 In contrast to the previously reported excess mortality, 37 only 1 patient in our series died from COVID-19. Of note, this patient presented late during the course of her disease to another hospital before being transferred to our ICU with rapid clinical deterioration, immediately requiring mechanical ventilation and extracorporeal membrane oxygenation support. This suggests that B-cell depleted patients with COVID-19 can benefit from close clinical observation to implement early and rigorous ICU support, including long-term mechanical ventilation.

Second, we observe a coincidence of rapid clinical deterioration and hematological recovery after immunochemotherapy, suggesting that particular close clinical monitoring is mandatory during this critical time period. Neutrophil recovery, further drop of lymphocyte counts, and especially an increasing neutrophil-to-lymphocyte ratio (NLR) 38,39 may be useful clinical indicators of impending respiratory decompensation.

In fact, the rapid rise of neutrophils and monocytes during hematological recovery could directly contribute to respiratory decompensation by facilitating myeloid cell recruitment to the lungs. 40 Of note, these cells are highly prevalent in inflammatory www.hemaspherejournal.com lung infiltrates in severe This may also explain the remarkably indolent clinical course of COVID-19 in our B-cell depleted patient (no. 6) who was not on active lymphoma treatment, and hence, did not undergo this phase of hematologic recovery during her infection. On the other hand, G-CSF is frequently administered to accelerate neutrophil recovery after immunochemotherapy for lymphoma, 30, 42, 43 as was the case with 4 of our 5 patients on active treatment. Therefore, our study should at least raise concerns over the routine use of G-CSF in these patients, and justifies further investigations. 44 Third, our study provides novel insights into the particular immune reactions in response to COVID-19 in B-cell depleted patients. We notice an early activation of the myeloid compartment, with subsequent hyperactivation of monocytes and pathological inflammation with high levels of IL-6, IL-10, IL-18 45 and others ("cytokine storm") 46,47 at the time of hematological recovery and clinical deterioration. However, due to limited size of our study, we realize that this data is primarily hypothesis-generating at this point and requires validation in larger cohorts with longer follow-up.

Finally, our study shows that B-cell depleted patients are incapable of developing lasting SARS-CoV-2 antibody responses, with long-term detectable viral RNA in upper respiratory tract specimens despite receiving convalescent plasma. In fact, we documented shedding of replication-competent virus over months, providing evidence that these patients are potentially capable of transmitting SARS-CoV-2 beyond commonly used quarantine periods. Furthermore, these patients remain at increased risk of SARS-CoV-2 reinfections, as has recently been documented in a case report. 19 Interestingly, all but 1 B-cell depleted patient ultimately eliminated SARS-CoV-2, yet it took them >6 times longer compared to controls. This strongly suggests that rapid virus elimination critically depends on virus-specific antibody responses. [48] [49] [50] In our series, administration of convalescence plasma resulted only in transient and low antibody levels in some patients and are therefore unlikely to have substantially contributed to virus elimination. Instead, we notice SARS-CoV-2-specific T-effector cell responses over time that are comparable to controls in the resolution phase of COVID-19 (data not shown). It remains to be studied, to what extent these T-cell responses actually contribute to virus elimination and whether they could potentially provide protective immunity in these patients. 51 We realize that the small cohort size is a major limitation of our study. Also, we only studied patients infected with the SARS-CoV-2 lineages B, B.1, and B.1.1 (data not shown) who were hospitalized during the first wave of the COVID-19 pandemic in Europe. As such, it remains unclear if these results are representative of the clinical course with other SARS-CoV-2 lineages or subsequent pandemic waves in other areas of the world. Importantly, however, our data with longterm follow-up complements previous retrospective studies 9,10,12 by an in-depth analysis of a homogenous cohort of patients with B-NHL who received B-cell depleting frontline immunochemotherapy. Our major findings are highly consistent and clinically relevant. Based on this study, we now take particular precautions at our institutions in managing COVID-19 in patients who have received B-cell depleting immunochemotherapies:

1. We admit all of these patients to the hospital irrespective of the severity of COVID-19 at the time of presentation. 2. We provide particular close monitoring at the time of hematological recovery and avoid the routine use of G-CSF. 3. We recommend early transfer to an ICU with experience in treating patients with COVID-19, prepared to provide long-term life-sustaining treatment. 4. We monitor these patients for long-term virus excretion and inform patients and their contacts (including health care providers) about the possibility of long-term infectivity and the risk of reinfections.

Ultimately, whenever clinically feasible, 13 we aim to vaccinate these patients prior to initiating B-cell depleting immunochemotherapies.

A novel coronavirus from patients with pneumonia in China

Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: recommendations for the second phase of the COVID-19 pandemic

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non-Hodgkin's lymphoma

B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?

Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis

Decreased B cells on admission associated with prolonged viral RNA shedding from the respiratory tract in coronavirus disease 2019: a case-control study

Rituximab treatment results in impaired secondary humoral immune responsiveness

Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report

Factors associated with prolonged viral RNA

Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer

Persistence and evolution of SARS-CoV-2 in an immunocompromised host

Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients

Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2

Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing

Virological assessment of hospitalized patients with COVID-2019

Guidelines for the use of flow cytometry and cell sorting in immunological studies

Duodenaltype and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles

Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Human monocyte subsets and phenotypes in major chronic inflammatory diseases

Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets

Monocyte subsets coregulate inflammatory responses by integrated signaling through TNF and IL-6 at the endothelial cell interface

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

Neutrophil-tolymphocyte ratio on admission is an independent risk factor for the severity and mortality in patients with coronavirus disease 2019

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induced hyperinflammation

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

An inflammatory cytokine signature predicts COVID-19 severity and survival

Antibody responses to SARS-CoV-2 in patients with COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in

T cells in COVID-19 -united in diversity

We would like to thank all CORKUM/CoMRI investigators and staff. The authors thank the patients and their families for their participation in the CORKUM/CoMRI registry. We acknowledge the iFlow Core Facility of the university hospital Munich (INST 409/225-1 FUGG) for assistance with the generation of flow cytometry data.

SR received travel grants from Gilead, TL received travel grants from Gilead, Pfizer and MSD. MD received research support from Abbvie, Bayer, Celgene, Janssen, Roche and speakers' honoraria from Bayer, Celgene, Gilead, Janssen, Roche. MD is part of the scientific advisory board of Astra Zeneca, Bayer, Beigene, Celgene, Gilead, Janssen, Novartis, Roche. All the other authors have no conflicts of interest to disclose.

OW was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)-Project no. 360372040-SFB 1335. MM and OTK are supported by the BMBF initiative "NaFoUniMedCovid19" (01KX2021), subproject B-FAST and COVIM, and the Bavaria-Saxony research alliance "FOR-COVID." CORKUM was supported by start-up funds of the LMU.